


Rheumatoid Arthritis




Abstract

Celecoxib Prodrugs were synthesized with 3 different biodegradable linkers, they were confirmed by different Spectroscopic techniques. Prodrug 1-3 were encapsulated into Nanoparticles via sole addition of DSPE-PEG₂₀₀₀. Physicochemical characterization of these NPs were analyze. Further these Nps were subjected to In vitro studies and found active against cytokines like TNF-∞, MCP-1 and IL-β. In Vivo studies reveal Nps are potent but comparatively Least active than celecoxib


Introduction

- Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) that selectively inhibits cyclooxygenase-2 (CoX-2) to alleviate inflammation.
- Despite its therapeutic benefits, it faces challenges, including low bioavailability, unfavorable pharmacokinetics, and potential cardiac toxicity.
- To enhance its efficacy, we have developed nanoparticles designed to improve hydrophobicity, biodegradability and stability profile.


Graphical Abstract




Synthesis and Characterization of Prodrugs (1-3)




Synthesis of Nanoparticles (Emulsion Evaporation)




Physicochemical Characterization of Nanoparticles



In Vitro Studies



In Vivo Studies (Prodrug-3 NPs)



Conclusion

We have successfully synthesized prodrugs of celecoxib with different biodegradable linkages using the C16 chain (1-3). Furthermore, we have synthesized nanoparticles with DSPE-PEG2000, which have an average size of 150 nm and a zeta potential of -32.5 mV. The encapsulation efficiency has been found to be 99%. In in vitro studies, these nanoparticles have shown activity against inflammatory cytokines. In in vivo studies, Prodrug-3 Nps have exhibited some activity against CIA mice, but they are not as effective as the free drug.

Future Prospects

- We are set to validate prodrugs 1 and 2 against CIA model mice.
- We plan to effectively design prodrugs that ensure sustained and controlled release in biological media with a detailed pharmacokinetics profile.

References

Saleem, R., Rehman, M. U., Hussain, S., Arif, A., Malik, H. N., Naqvi, F., & Jabeen, A. (2023). Nanoscale celecoxib prodrugs: As efficient anti-inflammatory principles. *Journal of Drug Delivery Science and Technology*, 90, 105089.

Acknowledgment

We would also like to acknowledge the organizers of Pakistan-France PERIDOT Research Mobility Program. No.PhaseVII-1/PERIDOT.R&D/HEC/2021), jointly implemented by the Higher Education Commission, Pakistan, and Ministry of Foreign Affairs & International. Development (MAEDI) and the Ministry of Higher Education and Research (MESRI), France.